' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Publikationen

Gewähltes Keyword: Abiraterone


Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.
Apostolidis, L; Nientiedt, C; Winkler, EC; Berger, AK; Kratochwil, C; Kaiser, A; Becker, AS; Jäger, D; Hohenfellner, M; Hüttenbrink, C; Pahernik, S; Distler, FA; Grüllich, C;
Oncotarget. 2019; 10(1): 17-29.
Originalarbeiten (Zeitschrift)
Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
Ponholzer, A; Loidl, W; Bektic, J; Dorfinger, K; Hruby, S; Jeschke, K; Kramer, G; Krause, S; Ludvik, G; Remzi, M; Roider, M; Stoiber, F;
Wien Klin Wochenschr. 2016; 128(3-4):156-163
Originalarbeiten (Zeitschrift)
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Höfner, T; Vallet, S; Hadaschik, BA; Pahernik, S; Duensing, S; Hohenfellner, M; Jäger, D; Grüllich, C;
World J Urol. 2015; 33(6): 833-839.
Originalarbeiten (Zeitschrift)